Javascript must be enabled to continue!
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS IN BRAZIL
View through CrossRef
The allogeneic hematopoietic stem cell transplant (allo-HCT) represents an important therapeutic strategy for acute leukemias, lymphomas and solid neoplasms, also used in benign diseases, such as aplastic anemia and inborn errors of immunity. This treatment requires myeloablative chemotherapy (conditioning regimen) followed by the infusion of donor-derived hematopoietic stem cells. However, this procedure carries some risks, such as infections, graft versus host disease (GVHD) and conditioning toxicity, which may result in transplant-related mortality. Over the decades, due to the increasing life expectancy and new advances in medicine, the cases of patients > 50 years with hematologic diseases that need allogeneic transplant have grown, requiring a comprehensive geriatric assessment as a mechanism for the best treatment option choice.
Objective: To apply a clinical frailty score and Karnofsky score in allogeneic hematopoietic stem cell older than 50 years old for three years in Walter Cantídio University Hospital (Fortaleza/Ceará) and in Amaral Carvalho Hospital (Jaú/São Paulo), expecting to recognize the profile of this patients and to demonstrate the relation between the clinical frailty score and overall survived, besides to estimate the contribution of GVHD prophylaxis and relapse in overall survival. Methods: Multicentric, retrospective, descriptive, analytical and quantitative study, acquiring dates by means of exams and medical record from Walter Cantídio University Hospital in Fortaleza/Ceará and Amaral Carvalho Hospital in Jaú/São Paulo. Results: The study selected 252 patients, 147 males and 105 females, sort in gender, disease, HCTCI score, CFS and KPS. In three years, the overall survival in FIT score is 2,46 years, while in FRAILTY score is 1,82 years. About the prophylaxis, the combination of cyclosporine, mycophenolate mofetil, cyclophosphamide had worse results than others prophylaxis. As expected, in case of relapse, there is shorter survival. Conclusion: The elderly population require a geriatric score in order to evaluate the profile of this patients once the allogeneic transplant must happen, then FIT patients has longer survival than FRAILTY patients.
Journal of Bone Marrow Transplantation and Cellular Therapy
Title: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS IN BRAZIL
Description:
The allogeneic hematopoietic stem cell transplant (allo-HCT) represents an important therapeutic strategy for acute leukemias, lymphomas and solid neoplasms, also used in benign diseases, such as aplastic anemia and inborn errors of immunity.
This treatment requires myeloablative chemotherapy (conditioning regimen) followed by the infusion of donor-derived hematopoietic stem cells.
However, this procedure carries some risks, such as infections, graft versus host disease (GVHD) and conditioning toxicity, which may result in transplant-related mortality.
Over the decades, due to the increasing life expectancy and new advances in medicine, the cases of patients > 50 years with hematologic diseases that need allogeneic transplant have grown, requiring a comprehensive geriatric assessment as a mechanism for the best treatment option choice.
Objective: To apply a clinical frailty score and Karnofsky score in allogeneic hematopoietic stem cell older than 50 years old for three years in Walter Cantídio University Hospital (Fortaleza/Ceará) and in Amaral Carvalho Hospital (Jaú/São Paulo), expecting to recognize the profile of this patients and to demonstrate the relation between the clinical frailty score and overall survived, besides to estimate the contribution of GVHD prophylaxis and relapse in overall survival.
Methods: Multicentric, retrospective, descriptive, analytical and quantitative study, acquiring dates by means of exams and medical record from Walter Cantídio University Hospital in Fortaleza/Ceará and Amaral Carvalho Hospital in Jaú/São Paulo.
Results: The study selected 252 patients, 147 males and 105 females, sort in gender, disease, HCTCI score, CFS and KPS.
In three years, the overall survival in FIT score is 2,46 years, while in FRAILTY score is 1,82 years.
About the prophylaxis, the combination of cyclosporine, mycophenolate mofetil, cyclophosphamide had worse results than others prophylaxis.
As expected, in case of relapse, there is shorter survival.
Conclusion: The elderly population require a geriatric score in order to evaluate the profile of this patients once the allogeneic transplant must happen, then FIT patients has longer survival than FRAILTY patients.
Related Results
Stem cells
Stem cells
What is a stem cell? The term is a combination of ‘cell’ and ‘stem’. A cell is a major category of living thing, while a stem is a site of growth and support for something else. In...
Donor-Derived Unlicensed NK Cells Promote the Hematopoietic Recovery after Allogeneic Hematopoietic Stem Cell Transplantation
Donor-Derived Unlicensed NK Cells Promote the Hematopoietic Recovery after Allogeneic Hematopoietic Stem Cell Transplantation
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for hematopoietic malignancies. Successful engraftment of hema...
UM171 Regulates the Hematopoietic Differentiation of Human Acquired Aplastic Anemia-Derived Induced Pluripotent Stem Cells
UM171 Regulates the Hematopoietic Differentiation of Human Acquired Aplastic Anemia-Derived Induced Pluripotent Stem Cells
Aplastic anemia (AA) is characterized by a hypoplastic bone marrow associated with low peripheral blood counts. In acquired cases, the immune system promotes hematopoietic stem and...
Arhgap21 Expression in Bone Marrow Niche Is Crucial for Hematopoietic Progenitor Homing and Short Term Reconstitution after Transplantation
Arhgap21 Expression in Bone Marrow Niche Is Crucial for Hematopoietic Progenitor Homing and Short Term Reconstitution after Transplantation
Abstract
The microenvironment of the bone marrow (BM) is essential for retention and migration of hematopoietic progenitor cells. ARHGAP21 is a negative regulator of...
Hematopoietic Cell Transplantation
Hematopoietic Cell Transplantation
Hematopoietic cell transplantation (HCT) can replace abnormal nonmalignant hematopoietic stem cells with cells from a healthy donor, making transplantation a potential cure for a v...
The Impact of Anti-HLA Antibodies on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome
The Impact of Anti-HLA Antibodies on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome
Objective To investigate the risk factors of positive anti-HLA antibodies in myelodysplastic syndrome (MDS) patients and gain insights into the impact of anti-HLA antibodies in all...
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
Human tissues comprise trillions of cells that populate a complex space of molecular phenotypes and functions and that vary in abundance by 4–9 orders of magnitude. Relying solely ...
Stem Cell Transplantation in Elderly Patients with Acute Lymphoblastic Leukemia (ALL) in First Complete Remission (CR1).
Stem Cell Transplantation in Elderly Patients with Acute Lymphoblastic Leukemia (ALL) in First Complete Remission (CR1).
Abstract
In the German Multicenter ALL studies (GMALL) patients aged >55 years with high risk (B-lineage ALL with WBC at diagnosis >30000, late CR, t (...

